Biocryst Pharmaceuticals (BCRX) Non-Current Assets (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Non-Current Assets came in at $91.4 million in Q1 2026, up 30.48% YoY from $70.1 million in Q1 2025, and down 16.74% on a QoQ basis from $109.8 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Non-Current Assets (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Non-Current Assets data on file, last reported at $91.4 million in Q1 2026.
- Quarterly Non-Current Assets rose 30.48% year-over-year to $91.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $350.7 million (up 12.55% YoY) and the FY2025 annual result came in at $109.8 million, up 60.42% from the prior year.
- Non-Current Assets retreated to $91.4 million in Q1 2026, from $109.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $109.8 million in Q4 2025 to a low of $15.7 million in Q2 2022.
- A 5-year average of $51.6 million and a median of $49.6 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets plunged 58.75% — and 2024, when it jumped 478.69%.
- Tracing BCRX's Non-Current Assets over 5 years: stood at $33.5 million in 2022, then slumped by 37.33% to $21.0 million in 2023, then jumped by 226.06% to $68.5 million in 2024, then soared by 60.42% to $109.8 million in 2025, then slipped by 16.74% to $91.4 million in 2026.
- The last three Non-Current Assets figures came in at $91.4 million (Q1 2026), $109.8 million (Q4 2025), and $90.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 73.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 73.17 Mn |
| Mar 31, 2026 | 91.43 Mn |
| Dec 31, 2025 | 109.81 Mn |
| Sep 30, 2025 | 90.74 Mn |
| Jun 30, 2025 | 58.73 Mn |
| Mar 31, 2025 | 70.07 Mn |
| Dec 31, 2024 | 68.45 Mn |
| Sep 30, 2024 | 64.13 Mn |
| Jun 30, 2024 | 108.96 Mn |
| Mar 31, 2024 | 20.79 Mn |
| Dec 31, 2023 | 20.99 Mn |
| Sep 30, 2023 | 20.46 Mn |
| Jun 30, 2023 | 18.83 Mn |
| Mar 31, 2023 | 18.85 Mn |
| Dec 31, 2022 | 33.50 Mn |
| Sep 30, 2022 | 49.59 Mn |
| Jun 30, 2022 | 15.69 Mn |
| Mar 31, 2022 | 16.01 Mn |
| Dec 31, 2021 | 22.02 Mn |
| Sep 30, 2021 | 13.02 Mn |